Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study

Metabolism: Clinical and Experimental

Volumn 58, Issue 8, 2009, Pages 1059-1066

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   Palumbo, Ilaria ^a   D'Angelo, Angela ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN; INSULIN; METFORMIN; PIOGLITAZONE;

ADULT; ANTHROPOMETRY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; MOTOR ACTIVITY; PATIENT EDUCATION AS TOPIC; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS; WEIGHT LOSS; YOUNG ADULT;

EID: 67651114145     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.03.007     Document Type: Article

References (32)

1. Gallagher E.J., LeRoith D., and Karnieli E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am 37 (2008) 559-579
2. Muniyappa R., Iantorno M., and Quon M.J. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am 37 (2008) 685-711
3. Toh S.A., and Rader D.J. Dyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers. Expert Rev Cardiovasc Ther 6 (2008) 1007-1022
4. Razani B., Chakravarthy M.V., and Sememnkovich C.F. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 37 (2008) 603-621
5. Preiss D., and Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci 115 (2008) 141-150
6. Abbasi F., Brown Jr. B.W., Lamendola C., McLaughlin T., and Reaven G.M. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40 (2002) 937-943
7. Kernan W.N., Inzucchi S.E., Viscoli C.M., Brass L.M., Bravata D.M., and Horwitz R.I. Insulin resistance and risk for stroke. Neurology 59 (2002) 809-815
8. Bailey C.J. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22 (2008) 215-224
9. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
10. Hanefeld M., and Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 6 (2008) 153-163
11. McCall A.L. Clinical review of glimepiride. Expert Opin Pharmacother 2 (2001) 699-713
12. Radikova Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocr Regul 37 (2003) 189-194
13. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28 (2007) 88-136
14. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care 24 (2001) S44-S47
15. Bunn H.F., Gabbay K.H., and Gallop P.M. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 200 (1978) 21-27
16. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
17. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8 (1972) 260-266
18. De Fronzo R.A., Tobin J.A., and Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 237 (1979) 214-223
19. Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 317 (1987) 350-357
20. Winer B.J. Statistical principles in experimental design. 2nd ed. (1971), McGraw-Hill, New York
21. Mari A., Ahrén B., and Pacini G. Assessment of insulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab Care 8 (2005) 529-533
22. Ahrén B., and Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 150 (2004) 97-104
23. Pacini G. The hyperbolic equilibrium between insulin sensitivity and secretion. Nutr Metab Cardiovasc Dis 16 (2006) S22-S27
24. Proks P., Reimann F., Green N., Gribble F., and Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 51 (2002) S368-S376
25. Derosa G., Gaddi A.V., Piccinni M.N., Salvadeo S., Ciccarelli L., Fogari E., et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 8 (2006) 197-205
26. Derosa G., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., Pricolo F., et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 37 (2007) 79-86
27. Mizuno C.S., Chittiboyina A.G., Kurtz T.W., Pershadsingh H.A., and Avery M.A. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem 15 (2008) 61-74
28. Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007) 386-399
29. Miyazaki Y., Matsuda M., and DeFronzo R.A. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 517-523
30. Groop L., Widén E., Franssila-Kallunki A., Ekstrand A., Saloranta C., Schalin C., et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32 (1989) 599-605
31. Korytkowski M., Thomas A., Reid L., Tedesco M.B., Gooding W.E., and Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 1607-1611
32. Pacini G., and Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 17 (2003) 305-322